Table 4.
Univariate and multivariate analysis of disease control rate.
| Univariate analysis | |||
|---|---|---|---|
|
| |||
| Disease control rate | |||
|
| |||
| All Patients | 23.2% (95% CI:18.9%–27.5%) | ||
| Sex | Male | 24% | P = .6 |
| Female | 22% | ||
|
| |||
| Age (years) | 0–39 | 24% | P = .2 |
| 40–59 | 27% | ||
| 60+ | 16% | ||
|
| |||
| Histology | Leiomyosarcoma | 19% | P = .2 |
| Synovial sarcoma | 34% | P = .07 | |
| Liposarcoma | 38% | P = .03 | |
| Other | 19% | ||
|
| |||
| Disease | Locally advanced | 18% | P = .1 |
| Metastatic—single organ | 29% | ||
| Metastatic—multiple organs | 17% | ||
|
| |||
| Sites of metastases | Involved versus uninvolved | ||
| Lung | 19% versus 29% | P = .04 | |
| Liver | 27% versus 22% | P = .4 | |
| Bone | 23% versus 23% | P = 1.0 | |
|
| |||
| Chemotherapy | Single agent/Phase I | 21% | P = .02 |
| Combination | 36% | ||
|
| |||
| Chemo Regimen | SA Doxorubicin | 27% | |
| SA Ifosfamide | 21% | ||
| Other SA | 22% | ||
| Phase I trial | 9% | ||
| Dox/Ifos combination | 38% | ||
| Other combination | 34% | ||
|
| |||
| Multivariate analysis | |||
|
| |||
| Relative likelihood of disease control (95% CI) | Significance | ||
|
| |||
| Pathology type | |||
| Liposarcoma versus other | 2.5 | 1.2–5.1 | P = .02 |
| Synovial versus other | 2.3 | 1.2–4.5 | P = .02 |
|
| |||
| Sites of disease | |||
| Lungs Involved | 0.6 | 0.3–1.0 | P = .04 |
|
| |||
| Not involved | 1.0 | ||
| Chemotherapy | |||
| Single Agent/Phase 1 Combination | 1.0 | 1.2–4.4 | P = .01 |
| 2.3 | |||
SA: single agent, Dox/ Ifos: Doxorubicin/Ifosfamide.